Filing Details
Silence Therapeutics plc (NASDAQ:SLN) filed a Form 8-K with the Securities and Exchange Commission on October 19, 2026, disclosing a material event.
8k filedNASDAQ:SLN
Silence Therapeutics plc (SLN) Reports Material Event to SEC
Silence Therapeutics plc (NASDAQ:SLN) filed a Form 8-K with the Securities and Exchange Commission on October 19, 2026, disclosing a material event.
At publication ·
What changed
Silence Therapeutics plc (NASDAQ:SLN) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Silence Therapeutics plc filed a Form 8-K on October 19, 2026, disclosing a material event to shareholders.
- The company's stock trades at $19.58 with a market capitalization of $304.2 million.
- Form 8-K filings report significant events such as leadership changes, material agreements, acquisitions, or financial guidance changes.
Market Context
Silence Therapeutics plc's stock currently trades at $19.58 with a market capitalization of $304.2M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Silence Therapeutics plc's stock.
All SEC filings for Silence Therapeutics plc are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SLN Stock Page
Frequently Asked Questions
Where can I read SLN's SEC filings?
Browse all filings on our SLN SEC filings page.
What types of SEC filings does Silence Therapeutics plc file?
Public companies like Silence Therapeutics plc file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.